Clinical trials: in Laos
Immunogenicity, Efficacy
New Generation mRNA Booster Vaccine Against Emerging VOCs
Primary：Objectives ：SafetyTo describe the safetyprofile of all participants in each group up to 6months post-dose.Immunogenicity：To demonstrate the superiorityof neutralizing antibodyresponse in terms of geometric mean titers…
- Conditions
- Immunogenicity, Efficacy, Safety
- Trial name
- NCT05580159
- Testing
- SW-BIC-213, SARS-Cov-2 Vaccina(Vero Cell ) Inactivated
- Where
- Laos
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
Immunogenicity, Safety
mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs
Primary#Objectives #Immunogenicity:To demonstrate the non-inferiority of binding antibody response in terms of geometric mean titers (GMT) of mRNA vaccine compare with mRNA COVID-19 vaccine(Pfizer) 14 days post dose.
- Conditions
- Immunogenicity, Safety, Efficacy
- Trial name
- NCT05686161
- Testing
- SW-BIC-213;SARS-Cov-2., Sinopharm (BIBP);SARS-Cov-2., Pfizer(BNT162b2);SARS-Cov-2.
- Where
- Laos
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics
COVID-19 Pandemic
A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above
This clinical trial is a phase I/II clinical trial to evaluate the safety, immunogenicity and immune persistence of COVID-19 mRNA vaccine in healthy people aged 18 years and above.
- Trial name
- NCT05144139
- Testing
- COVID-19 mRNA vaccine
- Where
- Laos
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Stemirna Therapeutics